good

Nur77 modulator 1 is an effective Nur77 binder (KD = 3.58 μM) that up-regulates Nur77 expression, mediates its sub-cellular localization, induces Nur77-dependent ER stress and autophagy, and leads to cell apoptosis, demonstrating anti-hepatoma activity.

Goodyeroside A is a natural glycoside that inhibits liver damage caused by substances such as carbon tetrachloride, and is also effective in suppressing inflammation by inhibiting the NF-κB signalling pathway.

TES is used to make buffer solutions in the pH range 6.8-8.2. TES has a pKa value of 7.550 (at 25°C).

LDL-IN-3 belongs to synthetic compounds and is an antioxidant and anti-atherosclerotic agent with good cell permeability and cardiovascular protective properties. This compound is used for the treatment of atherosclerosis-related diseases, effectively inhibiting oxidative stress and lipid deposition, and reducing arterial plaque formation.

LTB4-IN-1 (Anti-inflammatory agent 2, Compound 6) belongs to small molecule inhibitors and is a leukotriene B4 (LTB4) synthesis inhibitor (IC50 = 70 nM) with good anti-inflammatory activity. This compound can be used in experimental research on inflammation-related diseases.

D18024 belongs to phthalazinone derivatives and is a histamine H1 receptor antagonist with anti-allergic activity. This compound exhibits good selectivity and cell permeability, and can be used in research on allergic diseases such as chronic spontaneous urticaria.

Orforglipron (LY3502970) belongs to non-peptide small molecule GLP-1 receptor agonists and is a highly selective, orally effective GLP-1 receptor agonist with good cell permeability and oral bioavailability. This compound is used in research on type 2 diabetes and obesity, demonstrating significant glucose-lowering and weight-reducing activities.

ZT 52656A hydrochloride belongs to synthetic small molecule compounds and is a highly selective kappa opioid receptor (KOR) agonist with good receptor selectivity and potential peripheral action characteristics. This compound effectively prevents or significantly alleviates ocular pain through KOR activation, and can be used in pain-related mechanism research.

Meclinertant (SR 48692) is a small-molecule compound and a neurotensin receptor-1 (NTSR1) antagonist with good selectivity and cell permeability. This compound can be used to study neurotensin signaling pathways and related neurological diseases, and serves as a potential diagnostic and therapeutic probe targeting NTSR1-positive tumors.

PND-1186 (VS-4718) is a small molecule inhibitor, a highly specific, reversible FAK inhibitor (IC50=1.5 nM) with good selectivity and cell permeability. This compound inhibits FAK phosphorylation, blocking tumor cell survival, proliferation, migration, and angiogenesis, and is primarily used for anti-tumor research on solid tumors.

ATPγS tetralithium salt is a good substrate for RNA-stimulated nucleotide hydrolysis and RNA unwinding activity of eIF4A.

1. Ginkgetin has anti-influenza virus and anti-fungal activities. 2. Ginkgetin has anti-inflammatory activity, can down-regulates COX-2 induction in vivo against skin inflammatory responses. 3. Ginkgetin is a good STAT3 inhibitor and may be a useful lead

Sirpiglenastat (DRP-104) belongs to glutamine antagonist prodrugs and is a broad-spectrum glutamine metabolism inhibitor with tumor-selective activation, good tolerability, and oral activity. This compound is used in therapeutic research on various solid tumors.

Linvencorvir (RG7907) belongs to HBV core protein allosteric modulators (CpAM) and is an orally active HBV core protein inhibitor with potent anti-HBV activity, low CYP3A4 induction, and good metabolic stability. This compound is used for the treatment of chronic hepatitis B virus infection.

JNJ-6204 is a deuterated small molecule inhibitor, a dual CSNK1D/E inhibitor (CSNK1D IC50=2.3 nM; CSNK1E IC50=137 nM) with good brain permeability, which can be used for research on related diseases.

Suzetrigine (VX-548) is a small molecule inhibitor and a highly selective inhibitor of the NaV1.8 target, with oral activity and good peripheral nerve selectivity. Suzetrigine is used for the treatment of moderate to severe acute pain following abdominoplasty or bunionectomy.

VER-155008 is an Hsp70 inhibitor (IC50 = 0.5 μM), exhibiting over 100-fold selectivity against Hsp90, and capable of inhibiting Hsc70 and Grp78 (IC50 = 2.6 μM for both). This compound possesses good selectivity and cell permeability, and is used in anti-tumor research, showing therapeutic potential in leukemia and solid tumor models.

Nerandomilast (BI 1015550) is an orally active PDE4B inhibitor with IC50 of 7.2 nM. BI 1015550 has potential applications in inflammation, allergic diseases, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD) with a good safety profile.

GLF16 HCl (GLF16) belongs to fluorescent dyes and is a fluorescent Sudan Black B analog, serving as a non-targeted probe. This compound possesses good cell permeability and is suitable for live cells and in vivo environments. The probe enables rapid detection, isolation, and real-time tracking of senescent cells via fluorescence microscopy and flow cytometry.

BI-4020 is a fourth-generation, orally active, and non-covalent inhibitor of EGFR tyrosine kinase. It exhibits activity against the triple mutant EGFR del19 T790M C797S variant (IC50=0.2 nM in BaF3 cell lines), the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC50=1 nM), and EGFR wt (IC50=190 nM). BI-4020 also shows high kinome selectivity and good DMPK properties.

D-Cl-amidine is an effective and highly selective PAD1 inhibitor. D-Cl-amidine has a good correlation and no obvious toxicity.

DC_C66 DC_C66 has good selectivity for CARM1, PRMT1 (IC50 = 21μM), PRMT6 (IC50 = 47μM) and PRMT5. It is a cell-permeable, selective co-activator related arginine methyltransferase 1 (CARM1) inhibitor with IC50 of 1.8 μM.

DSP-0565 exhibits anti-convulsant activity and good safety margin in various models including scPTZ, 6 Hz, MES, and amygdala kindling. DSP-0565 can be used in studies about acting as a broad-spectrum anti-epileptic drug.

GLPG1205 is a potent, orally active GPR84 (G protein-coupled receptor) antagonist with anti-inflammatory activity. GLPG1205 shows good PK/PD characteristics and can be used to study pulmonary fibrosis.